Payer Contracting & Networks
Expert articles and analysis related to payer contracting & networks.
AI Summary — Last 7 Days
CMS’ 2027 Medicare Advantage landscape signals a continued network-and-benefit reset: plans are cutting offerings even as CMS projects lower average MA premiums, creating a sharper tradeoff between affordability headlines and reduced beneficiary/provider choice for VBC-aligned networks and risk-bearing provider groups. Under CMS Administrator Dr. Mehmet Oz, the Trump administration is also signaling tougher MA oversight—describing the program as a “garden” vulnerable to “weeds and overgrowth”—while quality bonus changes are poised to reprice performance based more heavily on data infrastructure and measurement mechanics than underlying clinical change, raising stakes for ACOs, MA partners, and delegated-risk providers. The near-term contracting implication is more selective payer-provider alignment: MA plans will likely prune markets and networks, while providers must prove measurable quality, coding integrity, and total-cost performance to remain preferred partners (MA plan cuts for 2027; Oz on MA oversight).
Related Articles
The pharmacy pays $1,302. The patient pays $299
By JOHN SAMARAS A US retail pharmacy pays $1,302 to acquire one month of branded Wegovy. That figure comes from the Centers for Medicare and Medicaid Services National Average Drug Acquisition CostCon...
How TrumpRx Brand-Name Drug Prices Compare to Other Countries
TrumpRx prices for brand-name drugs are about as likely to be higher as lower compared to average prices in other wealthy countries, according to an analysis that compares 32 brand-name drugs (without...
Analysis: Prices for Many Brand-Name TrumpRx Drugs Are Cheaper than the Average Price in Other Wealthy Countries, But Are Almost as Likely To Be More Expensive
Consumers who buy brand-name prescription drugs without an available generic or biosimilar at the prices available through the new TrumpRx website are about as likely to pay more as pay less for those...
Hospitals are scrambling to keep 340B discounts. Here’s what to know
Hospitals are scrambling to keep 340B discounts. Here’s what to know Modern Healthcare News
Waltz Health, Fresenius Kabi partner for direct-to-payer biosimilar program
Waltz Health, Fresenius Kabi partner for direct-to-payer biosimilar program Fierce Healthcare
GLP-1s spur a new calculation of healthcare value
The core tension in the policy debate around GLP-1 drugs is whether to view the products merely as a high-cost pharmacy benefit or more holistically through the prism of population health. In some way...
AMA analysis: PBM market concentration continues to rise - American Medical Association | AMA
AMA analysis: PBM market concentration continues to rise American Medical Association | AMA
After GLP-1s, biosimilars are the new frontier in direct-to-employer plans
Fresenius Kabi will sell biosimilars directly to employers. To accomplish that, the drugmaker is working with Eversana-owned Waltz Health, which runs a marketplace that helps employers shop for bett...
Understanding Specialty Drug Costs and How to Manage Them
Understanding Specialty Drug Costs and How to Manage Them Optum Business
15 million Americans live in a county with no general surgeon: 6 things to know
15 million Americans live in a county with no general surgeon: 6 things to know Becker's Physician Leadership